About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Nos2tm1Mrl
targeted mutation 1, Merck Research Laboratory
MGI:2158791
Summary 14 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Nos2tm1Mrl/Nos2tm1Mrl B6.129S7-Nos2tm1Mrl MGI:4837857
hm2
Nos2tm1Mrl/Nos2tm1Mrl either: 129S/Sv or B6J.129S7-Nos2tm1Mrl MGI:3041148
hm3
Nos2tm1Mrl/Nos2tm1Mrl involves: 129S7/SvEvBrd MGI:2672127
hm4
Nos2tm1Mrl/Nos2tm1Mrl involves: 129S7/SvEvBrd * C57BL/6 MGI:3041147
hm5
Nos2tm1Mrl/Nos2tm1Mrl involves: 129S7/SvEvBrd * PL/J MGI:4837858
cx6
Apoetm1Unc/Apoetm1Unc
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 MGI:4837860
cx7
ApcMin/Apc+
Msh2tm1Mak/Msh2tm1Mak
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J MGI:5636670
cx8
ApcMin/Apc+
Msh2tm1Mak/Msh2+
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J MGI:5636667
cx9
Nos1tm1Plh/Nos1tm1Plh
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129S4/SvJae * 129S7/SvEvBrd MGI:3789201
cx10
Nos2tm1Mrl/Nos2tm1Mrl
Nos3tm1Plh/Nos3tm1Plh
involves: 129S4/SvJae * 129S7/SvEvBrd MGI:3789203
cx11
Nos1tm1Plh/Nos1tm1Plh
Nos2tm1Mrl/Nos2tm1Mrl
Nos3tm1Plh/Nos3tm1Plh
involves: 129S4/SvJae * 129S7/SvEvBrd MGI:3789190
cx12
Nos1tm1Plh/Nos1tm1Plh
Nos2tm1Mrl/Nos2tm1Mrl
Nos3tm1Plh/Nos3tm1Plh
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 MGI:4837924
cx13
Nos2tm1Mrl/Nos2tm1Mrl
Tg(Myh6-Tnf)1.6Amf/?
involves: 129S7/SvEvBrd * C57BL/6 * FVB MGI:4837862
cx14
Faslpr/Faslpr
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129S7/SvEvBrd * MRL MGI:4837859


Genotype
MGI:4837857
hm1
Allelic
Composition
Nos2tm1Mrl/Nos2tm1Mrl
Genetic
Background
B6.129S7-Nos2tm1Mrl
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
skeleton
• in vitro differentiation is markedly attenuated (J:98070)
• in vitro differentiation is markedly attenuated (J:98070)
• decreased by 25% (J:98070)
• decreased by 25% (J:98070)
• resorption activity is considerably decreased (J:98070)
• resorption activity is considerably decreased (J:98070)
• bone mineral density of the femur is elevated at both 4 and 9 weeks of age (J:98070)
• bone mineral density of the femur is elevated at both 4 and 9 weeks of age (J:98070)
• total bone volume is increased (J:98070)
• total bone volume is increased (J:98070)
• increased cortical bone mass (J:98070)
• trabecular bone thickness and connectivity unchanged from controls (J:98070)
• increased cortical bone mass (J:98070)
• trabecular bone thickness and connectivity unchanged from controls (J:98070)

craniofacial
• distance between cementoenamel junction and alveolar bone crest is greater than for controls from 6 weeks on (without any bacterial challenge) (J:98070)
• distance between cementoenamel junction and alveolar bone crest is greater than for controls from 6 weeks on (without any bacterial challenge) (J:98070)

immune system
• in vitro differentiation is markedly attenuated (J:98070)
• in vitro differentiation is markedly attenuated (J:98070)
• decreased by 25% (J:98070)
• decreased by 25% (J:98070)
• resorption activity is considerably decreased (J:98070)
• resorption activity is considerably decreased (J:98070)
• do not respond to oral infection with Porphyromas gingivalis by bone loss (J:98070)
• serum levels of specific IgG are comparable to controls (J:98070)
• do not respond to oral infection with Porphyromas gingivalis by bone loss (J:98070)
• serum levels of specific IgG are comparable to controls (J:98070)

homeostasis/metabolism
• slightly elevated relative to controls (J:162957)
• slightly elevated relative to controls (J:162957)

hematopoietic system
• in vitro differentiation is markedly attenuated (J:98070)
• in vitro differentiation is markedly attenuated (J:98070)
• decreased by 25% (J:98070)
• decreased by 25% (J:98070)
• resorption activity is considerably decreased (J:98070)
• resorption activity is considerably decreased (J:98070)

endocrine/exocrine glands
• mammary gland regression after removal of pups is delayed (J:162957)
• degree of regression at 72 hours is similar to controls (J:162957)
• mammary gland development is normal at 10 days into lactation (J:162957)
• mammary gland regression after removal of pups is delayed (J:162957)
• degree of regression at 72 hours is similar to controls (J:162957)
• mammary gland development is normal at 10 days into lactation (J:162957)
• increase in apoptosis levels of involuting mammary glands is delayed (J:162957)
• increase in apoptosis levels of involuting mammary glands is delayed (J:162957)
• elevated milk production (J:162957)
• pups nourished by mutant mothers weigh more than pups nourished by control mothers (J:162957)
• elevated milk production (J:162957)
• pups nourished by mutant mothers weigh more than pups nourished by control mothers (J:162957)

integument
• mammary gland regression after removal of pups is delayed (J:162957)
• degree of regression at 72 hours is similar to controls (J:162957)
• mammary gland development is normal at 10 days into lactation (J:162957)
• mammary gland regression after removal of pups is delayed (J:162957)
• degree of regression at 72 hours is similar to controls (J:162957)
• mammary gland development is normal at 10 days into lactation (J:162957)
• increase in apoptosis levels of involuting mammary glands is delayed (J:162957)
• increase in apoptosis levels of involuting mammary glands is delayed (J:162957)
• elevated milk production (J:162957)
• pups nourished by mutant mothers weigh more than pups nourished by control mothers (J:162957)
• elevated milk production (J:162957)
• pups nourished by mutant mothers weigh more than pups nourished by control mothers (J:162957)

cellular
• in vitro differentiation is markedly attenuated (J:98070)
• in vitro differentiation is markedly attenuated (J:98070)

growth/size/body
• distance between cementoenamel junction and alveolar bone crest is greater than for controls from 6 weeks on (without any bacterial challenge) (J:98070)
• distance between cementoenamel junction and alveolar bone crest is greater than for controls from 6 weeks on (without any bacterial challenge) (J:98070)




Genotype
MGI:3041148
hm2
Allelic
Composition
Nos2tm1Mrl/Nos2tm1Mrl
Genetic
Background
either: 129S/Sv or B6J.129S7-Nos2tm1Mrl
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
N
• no difference in the number of oocytes released or survival of in vitro fertilized embryos is seen between female mutants and wild-type mice unlike in Nos3tm1Weo female mutants (J:73964)
• no difference in the number of oocytes released or survival of in vitro fertilized embryos is seen between female mutants and wild-type mice unlike in Nos3tm1Weo female mutants (J:73964)




Genotype
MGI:2672127
hm3
Allelic
Composition
Nos2tm1Mrl/Nos2tm1Mrl
Genetic
Background
involves: 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• about 80% survival rate at 10 months of age (J:100308)
• about 80% survival rate at 10 months of age (J:100308)
• about 20% die before 10 months of age (J:100308)
• about 20% die before 10 months of age (J:100308)

growth/size/body
• body weight is about 15% greater than controls (J:123048)
• body weight is about 15% greater than controls (J:123048)

immune system
• blood eosinophil numbers increase much less in OVA treated mice than in OVA treated controls (J:51635)
• blood eosinophil numbers increase much less in OVA treated mice than in OVA treated controls (J:51635)
• numbers of eosinophils in bronchoalveolar lavage fluid half of control numbers in OVA treated mice (J:51635)
• numbers of eosinophils in bronchoalveolar lavage fluid half of control numbers in OVA treated mice (J:51635)
• PGE2 production increase in response to stimulation with IFNgamma and LPS is considerably more modest than for controls (J:120499)
• PGE2 production increase in response to stimulation with IFNgamma and LPS is considerably more modest than for controls (J:120499)
• higher IFN gamma secretion by lung and splenic T cells (J:51635)
• higher IFN gamma secretion by lung and splenic T cells (J:51635)
• anesthetized mutants are substantially protected from septic shock induced by endotoxic lipopolysaccharide (LPS), however unanesthetized mutants exhibit as much LPS-induced liver damage as wild-type mice (J:25511)
• anesthetized mutants are substantially protected from septic shock induced by endotoxic lipopolysaccharide (LPS), however unanesthetized mutants exhibit as much LPS-induced liver damage as wild-type mice (J:25511)
• non-eosinophilic inflammatory responses are somewhat enhanced (J:51635)
• non-eosinophilic inflammatory responses are somewhat enhanced (J:51635)
• mutants succumb to lower doses of Listeria monocytogenes than wild-type mice, with approximate 100-fold greater bacterial burdens in liver and spleen (J:25511)
• mutants succumb to lower doses of Listeria monocytogenes than wild-type mice, with approximate 100-fold greater bacterial burdens in liver and spleen (J:25511)

cardiovascular system
N
• unlike in mice null for Nos3 no significant abnormalities in hypoxic pulmonary vasoconstriction or vasodilation in response to bradykinin are detected (J:57624)
• unlike in mice null for Nos3 no significant abnormalities in hypoxic pulmonary vasoconstriction or vasodilation in response to bradykinin are detected (J:57624)
• more vascularization of the retinal surface than seen in controls after 5 days of oxygen exposure followed by 120 hours of hypoxia (J:112024)
• more vascularization of the retinal surface than seen in controls after 5 days of oxygen exposure followed by 120 hours of hypoxia (J:112024)
• increase in right ventricle systolic pressure in mice exposed to chronic mild hypoxia compared to similarly treated wild-type controls (J:57624)
• increase in right ventricle systolic pressure in mice exposed to chronic mild hypoxia compared to similarly treated wild-type controls (J:57624)

homeostasis/metabolism
• reactive nitrogen intermediates do not increase in OVA treated mice as they do in OVA treated controls (J:51635)
• reactive nitrogen intermediates do not increase in OVA treated mice as they do in OVA treated controls (J:51635)
• significantly increased amounts of PxP2 are derived from platelet aggregation (J:120499)
• significantly increased amounts of PxP2 are derived from platelet aggregation (J:120499)
• considerably reduced amounts of PGE2 are excreted in urine (J:120499)
• also considerably reduced amounts of PGF2-like F2-isoprostanes excreted (J:120499)
• considerably reduced amounts of PGE2 are excreted in urine (J:120499)
• also considerably reduced amounts of PGF2-like F2-isoprostanes excreted (J:120499)
• callus cross-sectional area increased relative to controls during healing of fractured femora (J:123048)
• increased torsional failure during healing (J:123048)
• callus cross-sectional area increased relative to controls during healing of fractured femora (J:123048)
• increased torsional failure during healing (J:123048)
• wound closure is significantly delayed (J:46763)
• wound closure is significantly delayed (J:46763)

vision/eye
• more vascularization of the retinal surface than seen in controls after 5 days of oxygen exposure followed by 120 hours of hypoxia (J:112024)
• more vascularization of the retinal surface than seen in controls after 5 days of oxygen exposure followed by 120 hours of hypoxia (J:112024)
• intravitreal neovascularization is considerably less than in controls after 5 days of oxygen exposure followed by 120 hours of hypoxia (J:112024)
• intravitreal neovascularization is considerably less than in controls after 5 days of oxygen exposure followed by 120 hours of hypoxia (J:112024)

skeleton
• callus cross-sectional area increased relative to controls during healing of fractured femora (J:123048)
• increased torsional failure during healing (J:123048)
• callus cross-sectional area increased relative to controls during healing of fractured femora (J:123048)
• increased torsional failure during healing (J:123048)
• bone volume/trabecular volume is increased (J:150159)
• bone volume/trabecular volume is increased (J:150159)

renal/urinary system
• considerably reduced amounts of PGE2 are excreted in urine (J:120499)
• also considerably reduced amounts of PGF2-like F2-isoprostanes excreted (J:120499)
• considerably reduced amounts of PGE2 are excreted in urine (J:120499)
• also considerably reduced amounts of PGF2-like F2-isoprostanes excreted (J:120499)

hematopoietic system
• blood eosinophil numbers increase much less in OVA treated mice than in OVA treated controls (J:51635)
• blood eosinophil numbers increase much less in OVA treated mice than in OVA treated controls (J:51635)
• numbers of eosinophils in bronchoalveolar lavage fluid half of control numbers in OVA treated mice (J:51635)
• numbers of eosinophils in bronchoalveolar lavage fluid half of control numbers in OVA treated mice (J:51635)
• PGE2 production increase in response to stimulation with IFNgamma and LPS is considerably more modest than for controls (J:120499)
• PGE2 production increase in response to stimulation with IFNgamma and LPS is considerably more modest than for controls (J:120499)
• significantly increased amounts of PxP2 are derived from platelet aggregation (J:120499)
• significantly increased amounts of PxP2 are derived from platelet aggregation (J:120499)




Genotype
MGI:3041147
hm4
Allelic
Composition
Nos2tm1Mrl/Nos2tm1Mrl
Genetic
Background
involves: 129S7/SvEvBrd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• the large arteries of the uterus during pregnancy have thickened arterial walls and smaller lumina (J:78274)
• the large arteries of the uterus during pregnancy have thickened arterial walls and smaller lumina (J:78274)
• found in about 35% of homozygotes (J:97522)
• found in about 35% of homozygotes (J:97522)
• total ventricle weights are greater than controls for males only (J:101254)
• total ventricle weights are greater than controls for males only (J:101254)
• islet blood flow under basal conditions is increased (J:65562)
• islet blood flow under basal conditions is increased (J:65562)
• relative to controls (J:87980)
• streptozotocin induced diabetes for 8 days results in a more modest increase in blood pressure than in similar controls (J:87980)
• relative to controls (J:87980)
• streptozotocin induced diabetes for 8 days results in a more modest increase in blood pressure than in similar controls (J:87980)
• slightly increased at 3 months of age but not later (J:97522)
• slightly increased at 3 months of age but not later (J:97522)
• area of infarction is greater than for controls in non-diabetic mice after ischemia-reperfusion (J:87980)
• reperfusion injury is less in diabetic mice than in diabetic controls (J:87980)
• area of infarction is greater than for controls in non-diabetic mice after ischemia-reperfusion (J:87980)
• reperfusion injury is less in diabetic mice than in diabetic controls (J:87980)

homeostasis/metabolism
N
• normal serum insulin (J:65562)
• normal serum insulin (J:65562)
• obese mice on a high fat diet have normal insulin levels (J:72215)
• obese mice on a high fat diet have normal insulin levels (J:72215)
• area of infarction is greater than for controls in non-diabetic mice after ischemia-reperfusion (J:87980)
• reperfusion injury is less in diabetic mice than in diabetic controls (J:87980)
• area of infarction is greater than for controls in non-diabetic mice after ischemia-reperfusion (J:87980)
• reperfusion injury is less in diabetic mice than in diabetic controls (J:87980)
• slightly elevated levels (J:97522)
• slightly elevated levels (J:97522)
• levels 1.7 times normal at 9 months of age (J:97522)
• levels 1.7 times normal at 9 months of age (J:97522)
• elevated plasma triglycerides (J:155090)
• elevated plasma triglycerides (J:155090)
• slightly reduced at 3 months and tending to decline with age (J:97522)
• slightly reduced at 3 months and tending to decline with age (J:97522)
• resistant to hyperglycemia induced by multiple low doses of streptozotocin (J:65562)
• resistant to hyperglycemia induced by multiple low doses of streptozotocin (J:65562)
• hyperglycemic in the first 30 minutes of a glucose tolerance test (J:72215)
• return to fasting glucose levels by 90 minutes when controls are still hyperglycemic (J:72215)
• hyperglycemic in the first 30 minutes of a glucose tolerance test (J:72215)
• return to fasting glucose levels by 90 minutes when controls are still hyperglycemic (J:72215)
• the cyclic changes in estradiol level are abnormal in homozygous mutant females with the peak in estradiol concentration coming later than in 129/SvEv wild-type females (J:89542)
• the cyclic changes in estradiol level are abnormal in homozygous mutant females with the peak in estradiol concentration coming later than in 129/SvEv wild-type females (J:89542)
• plasma ACTH levels increase much more modestly after LPS treatment than for controls (J:109674)
• plasma ACTH levels increase much more modestly after LPS treatment than for controls (J:109674)
• plasma renin activity is increased (J:155090)
• plasma renin activity is increased (J:155090)
• volume of infarction 96 hours after middle cerebral artery occlusion is 28% smaller than controls (J:44287)
• volume of infarction is similar to controls 24 hours after cerebral artery occlusion (J:44287)
• volume of infarction 96 hours after middle cerebral artery occlusion is 28% smaller than controls (J:44287)
• volume of infarction is similar to controls 24 hours after cerebral artery occlusion (J:44287)
• protected from renal ischemia-reperfusion injury as indicated by lower serum creatine levels compared to controls (J:57621)
• less tubular necrosis, tubular structure is almost normal (J:57621)
• better survival rate at 24 hours after surgeries (J:57621)
• protected from renal ischemia-reperfusion injury as indicated by lower serum creatine levels compared to controls (J:57621)
• less tubular necrosis, tubular structure is almost normal (J:57621)
• better survival rate at 24 hours after surgeries (J:57621)

reproductive system
• the lining of the uterus during pregnancy shows a distinct lack of cellularity in homozygous female mutants compared to wild-type females (J:78274)
• the lining of the uterus during pregnancy shows a distinct lack of cellularity in homozygous female mutants compared to wild-type females (J:78274)
• diestrus length is increased in homozygous mutant females compared to 129/SvEv wild-type mice without an increase in total oestrus cycle length (J:89542)
• diestrus length is increased in homozygous mutant females compared to 129/SvEv wild-type mice without an increase in total oestrus cycle length (J:89542)
• by mid-gestation homozygous female mutants have significantly fewer viable embryos compared to wild-type females (J:78274)
• by mid-gestation homozygous female mutants have significantly fewer viable embryos compared to wild-type females (J:78274)

nervous system
N
• chronic nerve constriction does not lead to breakdown of small myelinated fibers (J:104959)
• chronic nerve constriction does not lead to breakdown of small myelinated fibers (J:104959)
• volume of infarction 96 hours after middle cerebral artery occlusion is 28% smaller than controls (J:44287)
• volume of infarction is similar to controls 24 hours after cerebral artery occlusion (J:44287)
• volume of infarction 96 hours after middle cerebral artery occlusion is 28% smaller than controls (J:44287)
• volume of infarction is similar to controls 24 hours after cerebral artery occlusion (J:44287)
• moderate breakdown of larger caliber myelinated fibers 5 days after chronic nerve constriction at a time when controls have far fewer surviving fibers (J:104959)
• fiber numbers are declining at 14 days but at a slower rate than for controls (J:104959)
• degenerating myelinated fibers persist longer after nerve crush injury (J:104959)
• moderate breakdown of larger caliber myelinated fibers 5 days after chronic nerve constriction at a time when controls have far fewer surviving fibers (J:104959)
• fiber numbers are declining at 14 days but at a slower rate than for controls (J:104959)
• degenerating myelinated fibers persist longer after nerve crush injury (J:104959)
• no regenerative myelinated sprouts at 21 days when they have begun to appear in controls (J:104959)
• regenerating fibers are smaller in caliber after nerve crush injury (J:104959)
• similar to controls by 6 weeks after nerve crush injury (J:104959)
• nerve fiber regeneration is delayed and new fibers are smaller in diameter after nerve transection (J:104959)
• no regenerative myelinated sprouts at 21 days when they have begun to appear in controls (J:104959)
• regenerating fibers are smaller in caliber after nerve crush injury (J:104959)
• similar to controls by 6 weeks after nerve crush injury (J:104959)
• nerve fiber regeneration is delayed and new fibers are smaller in diameter after nerve transection (J:104959)

behavior/neurological
• consume 1.6 times as much food as controls on a high fat diet (J:72215)
• consume 1.6 times as much food as controls on a high fat diet (J:72215)
• motor deficiencies improve between 24 and 96 hours after cerebral artery occlusion unlike controls (J:44287)
• motor deficiencies improve between 24 and 96 hours after cerebral artery occlusion unlike controls (J:44287)
• tactile hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls (J:104959)
• tactile hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls (J:104959)
• tactile allodynia observed at 3 weeks when neuropathic pain is diminishing in controls (J:104959)
• tactile allodynia observed at 3 weeks when neuropathic pain is diminishing in controls (J:104959)
• thermal hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls (J:104959)
• delayed thermal hypersensitivity observed at 3 weeks when neuropathic pain is diminishing in controls (J:104959)
• thermal hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls (J:104959)
• delayed thermal hypersensitivity observed at 3 weeks when neuropathic pain is diminishing in controls (J:104959)

immune system
• low level of islet inflammation as compared to controls when treated with streptozotocin (J:65562)
• islet size is normal (J:65562)
• low level of islet inflammation as compared to controls when treated with streptozotocin (J:65562)
• islet size is normal (J:65562)
• lower rejection rate of CBA/CaJ cardiac grafts (J:54764)
• lower levels of apoptosis by all measures used (J:54764)
• lower rejection rate of CBA/CaJ cardiac grafts (J:54764)
• lower levels of apoptosis by all measures used (J:54764)

renal/urinary system
• protected from renal ischemia-reperfusion injury as indicated by lower serum creatine levels compared to controls (J:57621)
• less tubular necrosis, tubular structure is almost normal (J:57621)
• better survival rate at 24 hours after surgeries (J:57621)
• protected from renal ischemia-reperfusion injury as indicated by lower serum creatine levels compared to controls (J:57621)
• less tubular necrosis, tubular structure is almost normal (J:57621)
• better survival rate at 24 hours after surgeries (J:57621)

endocrine/exocrine glands
• low level of islet inflammation as compared to controls when treated with streptozotocin (J:65562)
• islet size is normal (J:65562)
• low level of islet inflammation as compared to controls when treated with streptozotocin (J:65562)
• islet size is normal (J:65562)

growth/size/body
• body weight is greater than controls for males only (J:101254)
• body weight is greater than controls for males only (J:101254)
• experience greater weight gain on a high fat diet (J:72215)
• experience greater weight gain on a high fat diet (J:72215)

digestive/alimentary system
• do not respond to gastric luminal acid with as great an increase in gastric blood flow as do controls (J:84264)
• vascular resistance is not diminished (J:84264)
• do not respond to gastric luminal acid with as great an increase in gastric blood flow as do controls (J:84264)
• vascular resistance is not diminished (J:84264)
• mucus accumulation rate about 25% of controls (J:142280)
• firmly adherent layer of mucus is thinner than in controls (J:142280)
• mucus accumulation rate about 25% of controls (J:142280)
• firmly adherent layer of mucus is thinner than in controls (J:142280)

liver/biliary system
• fibrotic changes in the livers of mice on a high fat diet particularly around degenerating hepatocytes and the central vein area (J:94156)
• collagen fraction is higher than in controls when on a high fat diet (J:94156)
• fibrotic changes in the livers of mice on a high fat diet particularly around degenerating hepatocytes and the central vein area (J:94156)
• collagen fraction is higher than in controls when on a high fat diet (J:94156)

integument
• tactile hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls (J:104959)
• tactile hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls (J:104959)
• tactile allodynia observed at 3 weeks when neuropathic pain is diminishing in controls (J:104959)
• tactile allodynia observed at 3 weeks when neuropathic pain is diminishing in controls (J:104959)
• thermal hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls (J:104959)
• delayed thermal hypersensitivity observed at 3 weeks when neuropathic pain is diminishing in controls (J:104959)
• thermal hypersensitivity disappears between 5 and 14 days after the start of chronic nerve constriction while it persists through day 14 in controls (J:104959)
• delayed thermal hypersensitivity observed at 3 weeks when neuropathic pain is diminishing in controls (J:104959)




Genotype
MGI:4837858
hm5
Allelic
Composition
Nos2tm1Mrl/Nos2tm1Mrl
Genetic
Background
involves: 129S7/SvEvBrd * PL/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• levels of experimental autoimmune encephalitis are significantly greater than controls starting 13 days after injection with myelin basic protein (J:46192)
• remission levels are much lower than for controls (J:46192)
• levels of experimental autoimmune encephalitis are significantly greater than controls starting 13 days after injection with myelin basic protein (J:46192)
• remission levels are much lower than for controls (J:46192)




Genotype
MGI:4837860
cx6
Allelic
Composition
Apoetm1Unc/Apoetm1Unc
Nos2tm1Mrl/Nos2tm1Mrl
Genetic
Background
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apoetm1Unc mutation (22 available); any Apoe mutation (64 available)
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
N
• no effect on plasma cholesterol, triglycderide, or nitrate levels when compared to Apoetm1Unc controls on any diet tested (J:64566)
• no effect on plasma cholesterol, triglycderide, or nitrate levels when compared to Apoetm1Unc controls on any diet tested (J:64566)
• total cholesterol in the aorta is reduced 40% in males and 50% in females (J:64566)
• free cholesterol in the aorta is reduced 40% in males and 50% in females (J:64566)
• cholesterol ester in the aorta is reduced 57% in males and 72% in females (J:64566)
• total cholesterol in the aorta is reduced 40% in males and 50% in females (J:64566)
• free cholesterol in the aorta is reduced 40% in males and 50% in females (J:64566)
• cholesterol ester in the aorta is reduced 57% in males and 72% in females (J:64566)

growth/size/body
• females are slightly heavier than controls (J:64566)
• no weight effect in males (J:64566)
• females are slightly heavier than controls (J:64566)
• no weight effect in males (J:64566)

cardiovascular system
• lesions are smaller and flatter (J:64566)
• male lesions are 50% smaller (J:64566)
• female lesions are 30% smaller (J:64566)
• lesions are smaller and flatter (J:64566)
• male lesions are 50% smaller (J:64566)
• female lesions are 30% smaller (J:64566)




Genotype
MGI:5636670
cx7
Allelic
Composition
ApcMin/Apc+
Msh2tm1Mak/Msh2tm1Mak
Nos2tm1Mrl/Nos2tm1Mrl
Genetic
Background
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (8 available); any Apc mutation (53 available)
Msh2tm1Mak mutation (0 available); any Msh2 mutation (44 available)
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• mutants exhibit similar polyp formation in the small intestine and colon as mice heterozygous for ApcMin and homozygous for Msh2tm1Mak (J:200824)
• mutants exhibit similar polyp formation in the small intestine and colon as mice heterozygous for ApcMin and homozygous for Msh2tm1Mak (J:200824)




Genotype
MGI:5636667
cx8
Allelic
Composition
ApcMin/Apc+
Msh2tm1Mak/Msh2+
Nos2tm1Mrl/Nos2tm1Mrl
Genetic
Background
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (8 available); any Apc mutation (53 available)
Msh2tm1Mak mutation (0 available); any Msh2 mutation (44 available)
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• mutants exhibit enhanced polyp number in the small intestine, but not in the colon compared to double ApcMin Msh2tm1Mak heterozygotes (J:200824)
• mutants exhibit enhanced polyp number in the small intestine, but not in the colon compared to double ApcMin Msh2tm1Mak heterozygotes (J:200824)




Genotype
MGI:3789201
cx9
Allelic
Composition
Nos1tm1Plh/Nos1tm1Plh
Nos2tm1Mrl/Nos2tm1Mrl
Genetic
Background
involves: 129S4/SvJae * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nos1tm1Plh mutation (3 available); any Nos1 mutation (11 available)
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• 60-80% survival rate at 10 months of age (J:100308)
• 60-80% survival rate at 10 months of age (J:100308)
• about 20-40% die before 10 months of age (J:100308)
• about 20-40% die before 10 months of age (J:100308)

reproductive system
• slight reduction in the number of offspring produced from breeding pairs (J:100308)
• slight reduction in the number of offspring produced from breeding pairs (J:100308)

homeostasis/metabolism
• plasma osmolality is increased (J:100308)
• plasma osmolality is increased (J:100308)

renal/urinary system

behavior/neurological




Genotype
MGI:3789203
cx10
Allelic
Composition
Nos2tm1Mrl/Nos2tm1Mrl
Nos3tm1Plh/Nos3tm1Plh
Genetic
Background
involves: 129S4/SvJae * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
Nos3tm1Plh mutation (1 available); any Nos3 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• 60-80% survival rate at 10 months of age (J:100308)
• 60-80% survival rate at 10 months of age (J:100308)
• about 20-40% die before 10 months of age (J:100308)
• about 20-40% die before 10 months of age (J:100308)

reproductive system
• slight reduction in the number of offspring produced from breeding pairs (J:100308)
• slight reduction in the number of offspring produced from breeding pairs (J:100308)

cardiovascular system

homeostasis/metabolism
• plasma osmolality is increased (J:100308)
• plasma osmolality is increased (J:100308)

renal/urinary system

behavior/neurological




Genotype
MGI:3789190
cx11
Allelic
Composition
Nos1tm1Plh/Nos1tm1Plh
Nos2tm1Mrl/Nos2tm1Mrl
Nos3tm1Plh/Nos3tm1Plh
Genetic
Background
involves: 129S4/SvJae * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nos1tm1Plh mutation (3 available); any Nos1 mutation (11 available)
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
Nos3tm1Plh mutation (1 available); any Nos3 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Renal tubular apoptosis, regeneration, glomerulosclerosis and glomerular thrombus formation in Nos1tm1Plh/Nos1tm1Plh Nos2tm1Mrl/Nos2tm1Mrl Nos3tm1Plh/Nos3tm1Plh mice

mortality/aging
• only 3 of 13 mutants survive to 10 months of age (J:100308)
• only 3 of 13 mutants survive to 10 months of age (J:100308)
• only 3 of 13 mutants survive to 10 months of age (J:100308)
• only 3 of 13 mutants survive to 10 months of age (J:100308)

reproductive system
• the number of offspring produced from breeding pairs is significantly smaller than in wild-type (J:100308)
• the number of offspring produced from breeding pairs is significantly smaller than in wild-type (J:100308)

cardiovascular system
• all mutants that die show wall thickening, perivascular fibrosis, and adventitial mast cell infiltration of the coronary arteries (J:100308)
• all mutants that die show wall thickening, perivascular fibrosis, and adventitial mast cell infiltration of the coronary arteries (J:100308)
• glomerular thrombus formation (J:100308)
• glomerular thrombus formation (J:100308)
• 2 mutants that die within 10 months of age, have pulmonary and liver congestion (J:100308)
• 2 mutants that die within 10 months of age, have pulmonary and liver congestion (J:100308)
• in 2 mutants that die within 10 months of age (J:100308)
• in 2 mutants that die within 10 months of age (J:100308)
• in 2 mutants that die within 10 months of age (J:100308)
• in 2 mutants that die within 10 months of age (J:100308)
• heart rate is significantly lower than in wild-type, but similar to that of single Nos3 homozygotes, double Nos1/Nos3 homozygotes, and double Nos2/Nos3 homozygotes (J:100308)
• heart rate is significantly lower than in wild-type, but similar to that of single Nos3 homozygotes, double Nos1/Nos3 homozygotes, and double Nos2/Nos3 homozygotes (J:100308)
• hypertension is similar to single Nos3 homozygotes, double Nos1/Nos3 homozygotes, and double Nos2/Nos3 homozygotes (J:100308)
• hypertension is similar to single Nos3 homozygotes, double Nos1/Nos3 homozygotes, and double Nos2/Nos3 homozygotes (J:100308)
• systolic blood pressure is significantly higher in mutants than wild-type under conscious conditions (J:100308)
• systolic blood pressure is significantly higher in mutants than wild-type under conscious conditions (J:100308)
• the two mutants with pulmonary and liver congestion and acute renal tubular necrosis exhibit acute circulatory failure (J:100308)
• the two mutants with pulmonary and liver congestion and acute renal tubular necrosis exhibit acute circulatory failure (J:100308)

homeostasis/metabolism
• glomerular thrombus formation (J:100308)
• glomerular thrombus formation (J:100308)
• plasma concentrations of creatinine tend to be higher (J:100308)
• plasma concentrations of creatinine tend to be higher (J:100308)
• plasma osmolality is increased (J:100308)
• plasma osmolality is increased (J:100308)
• plasma concentrations of urea nitrogen are higher (J:100308)
• plasma concentrations of urea nitrogen are higher (J:100308)
• serum concentration is increased (J:150159)
• serum concentration is increased (J:150159)
• mutants exhibit only 2.4% and 3.6% of normal plasma and urinary NO levels, respectively (J:100308)
• mutants exhibit only 2.4% and 3.6% of normal plasma and urinary NO levels, respectively (J:100308)
• renal prostacyclin levels are significantly higher in 1 week old mutants than in wild-type (J:100308)
• renal prostacyclin levels are significantly higher in 1 week old mutants than in wild-type (J:100308)

renal/urinary system
• glomerular thrombus formation (J:100308)
• renal tubular lesions are seen predominantly in distal and collecting tubules than in proximal tubules (J:100308)
• glomerular thrombus formation (J:100308)
• renal tubular lesions are seen predominantly in distal and collecting tubules than in proximal tubules (J:100308)
• glomerular thrombus formation (J:100308)
• glomerular thrombus formation (J:100308)
• 2 mutants that die within 10 months of age have acute renal tubular necrosis (J:100308)
• 2 mutants that die within 10 months of age have acute renal tubular necrosis (J:100308)
• renal responsiveness to the anti-diuretic hormone, vasopressin, is reduced compared to wild-type, although central vasopressin release in unchanged (J:100308)
• impaired renal cAMP production (J:100308)
• renal responsiveness to the anti-diuretic hormone, vasopressin, is reduced compared to wild-type, although central vasopressin release in unchanged (J:100308)
• impaired renal cAMP production (J:100308)
• hypotonic polyuria (J:100308)
• hypotonic polyuria (J:100308)

behavior/neurological

digestive/alimentary system
• pyloric sphincter hypertrophy (J:100308)
• pyloric sphincter hypertrophy (J:100308)
• 3 of 5 mutants show enlargement of the stomach (J:100308)
• 3 of 5 mutants show enlargement of the stomach (J:100308)

liver/biliary system
• in 2 mutants that die within 10 months of age (J:100308)
• in 2 mutants that die within 10 months of age (J:100308)

respiratory system
• in 2 mutants that die within 10 months of age (J:100308)
• in 2 mutants that die within 10 months of age (J:100308)

skeleton
• at all time points (J:150159)
• increases slightly at 12 weeks of age (J:150159)
• at all time points (J:150159)
• increases slightly at 12 weeks of age (J:150159)
• trabecular bone in the proximal tibia is increased (J:150159)
• trabecular bone in the proximal tibia is increased (J:150159)
• increased osteoclast function (J:150159)
• higher in females than in males (J:150159)
• increased osteoclast function (J:150159)
• higher in females than in males (J:150159)
• bone formation rate and mineral apposition rate are increased (J:150159)
• higher in females than in males (J:150159)
• bone formation rate and mineral apposition rate are increased (J:150159)
• higher in females than in males (J:150159)

hematopoietic system
• increased osteoclast function (J:150159)
• higher in females than in males (J:150159)
• increased osteoclast function (J:150159)
• higher in females than in males (J:150159)

immune system
• increased osteoclast function (J:150159)
• higher in females than in males (J:150159)
• increased osteoclast function (J:150159)
• higher in females than in males (J:150159)

muscle
• pyloric sphincter hypertrophy (J:100308)
• pyloric sphincter hypertrophy (J:100308)

cellular

Mouse Models of Human Disease
OMIM ID Ref(s)
Diabetes Insipidus, Nephrogenic, Autosomal 125800 J:100308




Genotype
MGI:4837924
cx12
Allelic
Composition
Nos1tm1Plh/Nos1tm1Plh
Nos2tm1Mrl/Nos2tm1Mrl
Nos3tm1Plh/Nos3tm1Plh
Genetic
Background
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nos1tm1Plh mutation (3 available); any Nos1 mutation (11 available)
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
Nos3tm1Plh mutation (1 available); any Nos3 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• 85% of males die within 11 months whereas only 35-40% of males of any double homozygous genotype die at that time point (J:155090)
• 85% of males die within 11 months whereas only 35-40% of males of any double homozygous genotype die at that time point (J:155090)

cardiovascular system
• in most of the vasculature (J:155090)
• lipid accumulation in the aorta (J:155090)
• in most of the vasculature (J:155090)
• lipid accumulation in the aorta (J:155090)
• perivascular fibrosis of large epicardial coronary arteries and renal arteries (J:155090)
• perivascular fibrosis of large epicardial coronary arteries and renal arteries (J:155090)
• anterior and posterior ventricular walls are thickened (J:155090)
• anterior and posterior ventricular walls are thickened (J:155090)
• endothelium dependent relaxation lacking (J:155090)
• endothelium dependent relaxation lacking (J:155090)
• no vascular lesions in 2 month old males (J:155090)
• significant neointimal formation at 5 months (J:155090)
• medial thickening at 5 months (J:155090)
• no vascular lesions in 2 month old males (J:155090)
• significant neointimal formation at 5 months (J:155090)
• medial thickening at 5 months (J:155090)

adipose tissue
• perirenal and epididymal white adipose weights are increased (J:155090)
• perirenal and epididymal white adipose weights are increased (J:155090)

homeostasis/metabolism
• no vascular lesions in 2 month old males (J:155090)
• significant neointimal formation at 5 months (J:155090)
• medial thickening at 5 months (J:155090)
• no vascular lesions in 2 month old males (J:155090)
• significant neointimal formation at 5 months (J:155090)
• medial thickening at 5 months (J:155090)
• significantly increased after i.v. glucose (J:155090)
• significantly increased after i.v. glucose (J:155090)
• elevated plasma triglycerides (J:155090)
• elevated plasma triglycerides (J:155090)




Genotype
MGI:4837862
cx13
Allelic
Composition
Nos2tm1Mrl/Nos2tm1Mrl
Tg(Myh6-Tnf)1.6Amf/?
Genetic
Background
involves: 129S7/SvEvBrd * C57BL/6 * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
Tg(Myh6-Tnf)1.6Amf mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• isoproterenol improved fractional shortening relative to transgenic mice with Nos2 intact (J:109732)
• isoproterenol improved fractional shortening relative to transgenic mice with Nos2 intact (J:109732)
• isoproterenol improved left ventricular pressure development relative to transgenic mice with Nos2 intact (J:109732)
• isoproterenol improved left ventricular pressure development relative to transgenic mice with Nos2 intact (J:109732)

muscle
• isoproterenol improved fractional shortening relative to transgenic mice with Nos2 intact (J:109732)
• isoproterenol improved fractional shortening relative to transgenic mice with Nos2 intact (J:109732)




Genotype
MGI:4837859
cx14
Allelic
Composition
Faslpr/Faslpr
Nos2tm1Mrl/Nos2tm1Mrl
Genetic
Background
involves: 129S7/SvEvBrd * MRL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Faslpr mutation (24 available); any Fas mutation (47 available)
Nos2tm1Mrl mutation (4 available); any Nos2 mutation (12 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
renal/urinary system
• protein excretion less than controls at 20 weeks of age but not significantly (J:42666)
• protein excretion less than controls at 20 weeks of age but not significantly (J:42666)
• excrete very low levels of nitrite/nitrate relative to controls, heterozygotes are intermediate (J:42666)
• serum and urine levels of nitrite/nitrate are similar (J:42666)
• excrete very low levels of nitrite/nitrate relative to controls, heterozygotes are intermediate (J:42666)
• serum and urine levels of nitrite/nitrate are similar (J:42666)

homeostasis/metabolism
• serum and urine levels of nitrite/nitrate are similar (J:42666)
• serum and urine levels of nitrite/nitrate are similar (J:42666)
• protein excretion less than controls at 20 weeks of age but not significantly (J:42666)
• protein excretion less than controls at 20 weeks of age but not significantly (J:42666)
• excrete very low levels of nitrite/nitrate relative to controls, heterozygotes are intermediate (J:42666)
• serum and urine levels of nitrite/nitrate are similar (J:42666)
• excrete very low levels of nitrite/nitrate relative to controls, heterozygotes are intermediate (J:42666)
• serum and urine levels of nitrite/nitrate are similar (J:42666)

immune system
N
• vasculitis absent in renal vessels, unlike controls (J:42666)
• anti-DNA levels similar to controls (J:42666)
• vasculitis absent in renal vessels, unlike controls (J:42666)
• anti-DNA levels similar to controls (J:42666)
• IgG1/IgG3 ratio is higher than controls (J:42666)
• IgG1/IgG3 ratio is higher than controls (J:42666)
• significantly reduced rheumatoid factor specific IgG antibodies (J:42666)
• significantly reduced rheumatoid factor specific IgG antibodies (J:42666)
• significantly reduced rheumatoid factor specific IgM antibodies (J:42666)
• significantly reduced rheumatoid factor specific IgM antibodies (J:42666)

hematopoietic system
• IgG1/IgG3 ratio is higher than controls (J:42666)
• IgG1/IgG3 ratio is higher than controls (J:42666)
• significantly reduced rheumatoid factor specific IgG antibodies (J:42666)
• significantly reduced rheumatoid factor specific IgG antibodies (J:42666)
• significantly reduced rheumatoid factor specific IgM antibodies (J:42666)
• significantly reduced rheumatoid factor specific IgM antibodies (J:42666)





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory